The disputed patent was originally awarded to Idenix Pharmaceuticals, which Merck acquired in 2014. Gilead obtained sofosbuvir as part of its acquisition of the biotech firm Pharmasset in 2011. The legal dispute turned on whether Pharmasset derived sofosbuvir from an Idenix patent or whether it …
